0001567264 false 0001567264 2023-08-14 2023-08-14 0001567264 dei:FormerAddressMember 2023-08-14 2023-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares










Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): August 14, 2023


Intensity Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware   001-41109   46-1488089

(State or Other Jurisdiction

of Incorporation) 

  (Commission File Number)   

(IRS Employer

Identification No.) 


1 Enterprise Drive, Suite 430

Shelton, CT

(Address of Principal Executive Offices)   (Zip Code)


(203) 221-7381 

(Registrant’s Telephone Number, Including Area Code)


61 Wilton Road, 3rd Floor

Westport, CT 06880

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class:   Trading Symbol(s):   Name of Exchange on Which Registered:
Common Stock, $0.0001 par value per share   INTS   The NASDAQ Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 






Item 2.02 Results of Operations and Financial Condition.

On August 14, 2023, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the quarter ended June 30, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.


The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.   Description
99.1   Press Release issued August 14, 2023.
104   Cover Page Interactive Data File (formatted in Inline XBRL).




Comments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” sections of the Company’s prospectus, dated June 29, 2023 and filed on June 30, 2023 pursuant to Rule 424(b) under the Securities Act relating to the Company’s Registration Statement on Form S-1 (File No. 333-260565). The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates. 







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: August 14, 2023


  Intensity Therapeutics, Inc.
  By: /s/ Lewis H. Bender
    Name: Lewis H. Bender
    Title: Chief Executive Officer


[Signature Page to the Form 8-K]